Tdap Vaccine Safety for Plasma Donors
A Clinical Study of the Safety and Antibody Responses of Plasma Donors Vaccinated With a Licensed Tdap Vaccine
Sponsor: GCAM Inc.
A PHASE2/PHASE3 clinical study on Tetanus, this trial is completed. The trial is conducted by GCAM Inc. and has accumulated 9 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Jun 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GCAM Inc.
For direct contact, visit the study record on ClinicalTrials.gov .